Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vascular pleiosynergy--does it really work?

Albert Császár1

  • 1Department of Medicine, National Health Center, Budapest, Hungary. csaszalb@ogyik.hu

Current Vascular Pharmacology
|November 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The characteristics of two LDL-cholesterol level reduction treatment strategies, "treat-to-target" and "percent reduction": an observational study without intervention.

BMC cardiovascular disorders·2019
Same author

Elevation of monocyte-platelet aggregates is an early marker of type 2 diabetes.

Interventional medicine & applied science·2013
Same author

Roles of Mac-1 and glycoprotein IIb/IIIa integrins in leukocyte-platelet aggregate formation: stabilization by Mac-1 and inhibition by GpIIb/IIIa blockers.

Platelets·2012
Same author

Correlations between prescription of anti-hypertensive medication and mortality due to stroke.

BMC cardiovascular disorders·2012
Same author

Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.

Clinical drug investigation·2012
Same author

Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.

Diabetes & vascular disease research·2012
Same journal

Chronic Treatment with Renin-Angiotensin System Inhibitors at Hospital Admission is Associated with Improved Reperfusion and Mortality Among STEMI Patients Undergoing Mechanical Reperfusion: Insight from the ISACS-STEMI COVID-19 Registry.

Current vascular pharmacology·2026
Same journal

Steps to Walk Out of, or Side Track, Cardiovascular Disease to Achieve Longevity.

Current vascular pharmacology·2026
Same journal

Mast Cells and Cardiovascular Disorders.

Current vascular pharmacology·2026
Same journal

Occupational and Environment-Related Cardiovascular Disease: A Comprehensive Review of the Literature.

Current vascular pharmacology·2026
Same journal

Metalloproteinases 2 and 9 as Biomarkers in Acute Elevation of Blood Pressure.

Current vascular pharmacology·2026
Same journal

Is the Cardiovascular Risk Increased in Patients with Isolated Systolic Hypertension and Anemia?

Current vascular pharmacology·2026
See all related articles

Multiple cardiovascular risk factors amplify risk, but combined treatments multiply benefits. Some drugs offer additional advantages through pleiotropic effects, a phenomenon termed pleiosynergy, enhancing therapeutic outcomes.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Cardiovascular disease risk escalates with multiple contributing factors.
  • Simultaneous treatment of these factors can yield synergistic therapeutic benefits.
  • Certain medications possess pleiotropic effects extending beyond their primary therapeutic actions.

Purpose of the Study:

  • To define and explore the concept of pleiosynergy in pharmacology.
  • To investigate pleiotropic effects of lipid-lowering statins and third-generation calcium channel blockers.
  • To understand how these additional effects contribute to overall cardiovascular health.

Main Methods:

  • Literature review of studies on statins and calcium channel blockers.
  • Analysis of reported pleiotropic mechanisms, including nitric oxide (NO) production, antioxidant activity, and smooth muscle cell modulation.

Related Experiment Videos

  • Conceptual framework development for pleiosynergy.

    • Main Results:

    • Statins and third-generation calcium channel blockers exhibit significant pleiotropic effects.
    • These effects include enhanced endothelial nitric oxide (NO) production, reduced free radical formation, and inhibition of smooth muscle cell migration and proliferation.
    • These additional actions are independent of the drugs' primary lipid-lowering or blood pressure-reducing effects.

    Conclusions:

    • Pleiotropic effects of cardiovascular drugs can lead to 'therapeutic cross effects'.
    • This phenomenon, defined as pleiosynergy, enhances overall treatment efficacy.
    • Understanding pleiosynergy offers new perspectives for cardiovascular drug development and combination therapy.